PLIANT THERAPEUTICS INC. - COMMON STOCK

Pliant Therapeutics Presents Preclinical Data Highlighting A Novel Approach for the Treatment of Muscular Dystrophies

22 Jun 2022 08:00:00 By Nasdaq GlobeNewswire

Pliant Therapeutics Announces Advancement of Integrin Target in Fibrosis Under Strategic Collaboration

16 Jun 2022 08:00:02 By Nasdaq GlobeNewswire

Pliant Therapeutics Announces Presentations at the International Liver Congress™ 2022

15 Jun 2022 16:01:00 By Nasdaq GlobeNewswire

Pliant Therapeutics Announces Presentations at 2022 American Thoracic Society International Conference

18 May 2022 11:15:00 By Nasdaq GlobeNewswire

Pliant Therapeutics to Participate in Upcoming Investor Conferences

11 May 2022 08:00:01 By Nasdaq GlobeNewswire

Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results

09 May 2022 16:05:01 By Nasdaq GlobeNewswire

Pliant Therapeutics Enters into $100 million Loan Facility Agreement with Oxford Finance to Support Ongoing Development of PLN-74809

05 May 2022 08:00:03 By Nasdaq GlobeNewswire

Pliant Therapeutics Receives FDA Fast Track Designation for PLN-74809 for the Treatment of Idiopathic Pulmonary Fibrosis

03 May 2022 08:00:02 By Nasdaq GlobeNewswire

Pliant Therapeutics Announces Multiple Presentations at the 2022 American Thoracic Society International Conference

02 May 2022 08:00:03 By Nasdaq GlobeNewswire

Pliant Therapeutics to Participate in Needham Healthcare Conference

05 Apr 2022 08:03:00 By Nasdaq GlobeNewswire

CORRECTION - Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results

28 Feb 2022 19:43:43 By Nasdaq GlobeNewswire

Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results

28 Feb 2022 16:05:00 By Nasdaq GlobeNewswire

Pliant Therapeutics Announces Positive Data from Expanded Phase 1b BAL Trial of PLN-74809 Demonstrated Suppression of TGF-β Signaling in Healthy Volunteers

28 Feb 2022 08:00:01 By Nasdaq GlobeNewswire

Pliant Therapeutics Announces Positive DSMB Safety Review and Commencement of Enrollment of Phase 2a Trial of PLN-74809 at 320 mg Dose in Idiopathic Pulmonary Fibrosis

24 Feb 2022 17:41:07 By Nasdaq GlobeNewswire

Pliant Therapeutics to Participate in Upcoming Investor Conferences

24 Feb 2022 08:03:00 By Nasdaq GlobeNewswire

Pliant Therapeutics Highlights Recent Developments for Lead Program PLN-74809 and Expected 2022 Milestones

11 Jan 2022 08:03:00 By Nasdaq GlobeNewswire

Pliant Therapeutics to Participate in the 40th Annual J.P. Morgan Healthcare Conference

21 Dec 2021 08:06:00 By Nasdaq GlobeNewswire

Pliant Therapeutics to Participate in Upcoming Investor Conferences

18 Nov 2021 08:00:02 By Nasdaq GlobeNewswire

Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2021 Financial Results

09 Nov 2021 16:06:00 By Nasdaq GlobeNewswire

Pliant Therapeutics to Participate in Piper Sandler Lung Day

07 Oct 2021 08:06:00 By Nasdaq GlobeNewswire